HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

Exelixis' Cabometyx successor fails primary endpoint in colorectal cancer trial amid FDA review

Exelixis' next franchise drug, zanzalintinib, has hit a clinical setback, although at least two groups of analysts suggested that an FDA approval is still on the table.

By FierceBiotech · Jun 23, 2026 · via FierceBiotech
Exelixis' Cabometyx successor fails primary endpoint in colorectal cancer trial amid FDA review

Image: FierceBiotech

This is an aggregated industry headline. Read the full story at FierceBiotech →

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
US to investigate Germany's proposed drug spending reforms
Amid efforts in Germany to retool the country's drug spending, the U.S. is launching an investigation into wha…
Jun 23, 2026
CARsgen Wins First-Ever Solid Tumor CAR-T Approval in China
The WeekBriefing
CARsgen Wins First-Ever Solid Tumor CAR-T Approval in China
China grants CARsgen approval for a Claudin18.2-targeted therapy, marking the first CAR-T authorized for solid…
Jun 23, 2026
STAT+: Eli Lilly gave extraordinary obesity drug access to a 79-year-old patient. Who was it?
The WeekSTAT News ↗
STAT+: Eli Lilly gave extraordinary obesity drug access to a 79-year-old patient. Who was it?
Exclusive: STAT has learned that Eli Lilly and the FDA allowed a 79-year-old to gain extraordinary access to a…
Jun 23, 2026